BrightHeart, developer of an artificial intelligence platform for obstetric ultrasound, announced an €11 million Series A on January 8, 2026. The round was co-led by Odyssée Venture and GO Capital, with participation from the Mussallem CHD Alliance, Lift Value, the IDAHO HealthTech Club, and existing investor Sofinnova Partners. The funds will be used to roll out the platform in the United States and Europe.
A Series A to scale an AI already cleared by the FDA
The deal, detailed in the BusinessWire press release, comes on the heels of an FDA clearance obtained in November 2024 — the first of its kind for AI software dedicated to fetal cardiac assessment. The company markets its platform under the name B-Right.
Three uses of the funds have been announced:
- Commercial rollout in the United States, the leading paying market for AI-assisted radiology.
- Expansion in Europe with a focus on CE marking and integration with existing hospital systems.
- Product R&D to extend the platform to the full second-trimester fetal anatomy scan.
The medical problem: 50% of congenital heart defects go undetected before birth
Congenital heart disease (CHD) is the leading cause of malformation-related neonatal death. A meta-analysis published in eClinicalMedicine (The Lancet) notes that the average prenatal detection rate hovers around 48% and drops below 10% in some rural areas. The contributing factors are well known: a shortage of trained sonographers, limited examination time, and inconsistent quality of the imaging planes obtained.
BrightHeart addresses precisely this point: the platform automatically detects the standard views required for cardiac evaluation (4-chamber view, outflow tracts, 3-vessel view, etc.) and alerts the operator if a plane is non-compliant. According to a clinical study reported by BusinessWire, the tool raises the detection rate to over 96% under study conditions. The meta-analysis published in The Lancet found, across all the AI models evaluated, a pooled sensitivity of 0.89 and a specificity of 0.91 for detecting fetal cardiac anomalies.
Market: an AI radiology segment that remains highly fragmented
The global market for AI in medical imaging is estimated at between $1.5 and $2 billion in 2025, with a consensus CAGR of 30 to 40% by 2030. Obstetrics, however, still lags behind mammography or chest CT in terms of penetration. Several reasons:
- Heterogeneity of ultrasound devices, handheld vs cart-based, which complicates generic models.
- Lack of a pricing incentive in most European reimbursement systems.
- Cultural sensitivity around prenatal diagnosis, which slows down rapid rollouts.
BrightHeart benefits from a more favorable environment in the United States, where CPT codes related to AI in imaging have been advancing since 2023, and where several commercial payers now reimburse AI assistance when it is clinically justified.
Competition: a quartet to watch
The prenatal ultrasound AI segment is structured around a handful of players:
- GE HealthCare integrates native fetal cardiac AI features into its Voluson devices.
- Philips is developing its Anatomical Intelligence Ultrasound module.
- Caption Health (acquired by GE in 2023) focuses on adult cardiac ultrasound instead.
- Sonio, a French scale-up, offers an exam-quality software layer, but without a CHD-specific positioning.
BrightHeart stands out through its pure-play obstetric cardiac focus and its specific FDA clearance, which constitutes a temporary barrier to entry. The presence of the Mussallem CHD Alliance — a philanthropic foundation linked to the Mussallem family (Edwards Lifesciences) — is also a signal of the clinical rigor behind the case.
Business model and go-to-market
The go-to-market model is based on an annual software license sold to imaging centers, hospitals, and obstetrics practices. The value proposition rests on three pillars: improved detection rates, reduced examination time, and standardized image quality. For medical directors, ROI comes from limiting unnecessary transfers (false positives) and, above all, from preventing emergency neonatal care (true positives detected late).
Healthtech sales teams structuring their growth strategy around long sales cycles (12-18 months in hospital settings) will find a textbook case here: FDA-cleared product + pivotal studies + KOL clinics + academic deployment before community rollout.
Risks and watchpoints
Three areas to watch:
- Adoption by senior sonographers: perceived added value drops among highly experienced operators, creating a friction risk during deployment.
- Reimbursement trends in the United States and even more so in Europe, where coverage for AI tools remains highly uneven.
- Competition from imaging giants that can natively integrate equivalent features into their new devices.
What this means for the French digital health ecosystem
BrightHeart, based in Paris and co-founded by French clinicians and engineers, illustrates the growing maturity of AI applied to medical imaging. The positioning — FDA clearance first, then scaling across Europe — is becoming the dominant pattern for ambitious medical SaaS companies: FDA regulatory complexity is offset by the predictability of the US market, while Europe remains fragmented.
FAQ
How much has BrightHeart raised?
BrightHeart raised €11 million in a Series A announced on January 8, 2026. The round was co-led by Odyssée Venture and GO Capital, with participation from Sofinnova Partners, the Mussallem CHD Alliance, Lift Value and the IDAHO HealthTech Club.
What does BrightHeart actually do?
The company develops the B-Right platform, AI software that assists sonographers during prenatal scans to automatically detect standard cardiac views and identify signs of congenital heart defects in the fetus.
Is the software approved?
Yes, BrightHeart received FDA clearance in November 2024 — the first ever granted to AI software dedicated to fetal cardiac assessment. CE marking is underway for the European market.
How much does the tool improve detection?
A study published in Obstetrics & Gynecology reports a detection rate above 96% with BrightHeart assistance, compared with a global average of around 48% in routine practice, according to meta-analyses published in The Lancet.
What will the funds raised be used for?
Three priorities: commercialization in the United States, expansion in Europe with CE marking, and product development to cover the full second-trimester anatomical examination.